Ovarian Cancer

>

Latest News

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.
Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer

March 28th 2024

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.
Avutometinib Combo Yields Responses in Serous Ovarian Cancer Subgroups

March 26th 2024

Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.
Rezatapopt Yields Early Responses, Safety in Advanced Ovarian Cancer

March 24th 2024

Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.
FDA Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

March 22nd 2024

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.
CRX100 Yields Responses, Tolerability in Platinum-Resistant Ovarian Cancer

March 19th 2024

Video Series
Video Interviews
Podcasts
Latest CME Events & Activities

What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations

View More

Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS

View More

Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond

View More

Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?

View More

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

View More

Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care

View More

The Latest on Acute Lymphocytic Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

A Focus on Acute Myeloid Leukemia

View More

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?

View More

Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma

View More

Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer

View More

Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse

View More

Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs

View More

Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Go To PER in Chicago

May 31, 2024 - June 2, 2024

Register Now!

The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward

View More

Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment

View More

Expert Illustrations & Commentaries™: Exploring the Mechanistic Rationale for Targeting FGFR2 and Pan-FGFR in CCA

View More

Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician

View More

Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure

View More

The 14th Asia-Pacific Primary Liver Cancer Expert Meeting

July 18 - 20, 2024

Register Now!

23rd Annual International Congress on the Future of Breast Cancer® East

July 19-20, 2024

Register Now!

More News